絞り込み

16555

広告

職員以外も加算 ケアマネなど、処遇改善 (毎日新聞)

厚生労働省は15日、来年10月の消費増税に合わせた介護職員の処遇改善策について、介護報酬の加算分を介護職員以外の職種の給与増に使うことを認める方針を示した。対象...

  1. 温暖化でビール高値に 大麦の収穫減で -...
  2. 温暖化でビール高値に - 徳島新聞
  3. 温暖化でビール高値に (デイリースポーツ...
  4. 温暖化でビール高値に 大麦の収穫減、今世...

ニュース一覧

Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer.

著者 Brodowicz T , Hadji P , Niepel D , Diel I
Cancer Treat Rev.2017 Oct 18 ; 61():23-34.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (48view , 0users)

Full Text Sources

Medical

Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability. Biomarkers of bone turnover may also have a role in the early detection of bone metastases and can provide valuable prognostic information on disease progression. SREs can be delayed or prevented using agents such as the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, denosumab, and bisphosphonates. Painful bone metastases can be treated with radiofrequency ablation, radiotherapy, or radionuclides such as radium-223 dichloride, which has been shown to delay the onset of SREs in men with castration-resistant prostate cancer. Close monitoring of bone health in patients with advanced cancer may lead to early identification of individuals with bone metastases who could benefit from early intervention to prevent SREs. This review examines current guideline recommendations for assessing and monitoring bone health in patients with advanced cancer, use of biomarkers and treatment of patients with bone metastases. The emerging evidence for the potential survival benefit conferred by early intervention with denosumab and bisphosphonates is also discussed, together with best practice recommendations.
PMID: 29100167 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード